TABLE 4.
Pathotypes of PMMoV genotypes used in this work
| Virus genotype | Phenotype forb: |
Pathotype | |||
|---|---|---|---|---|---|
| L1/L1 | L2/L2 | L3/L3 | L4/L4 | ||
| MG | + | + | NLL | NLL | P1,2 |
| MG-(M138N)a | + | + | + | NLL | P1,2,3 |
| MG-(T43K+D50G)a | + | + | + | NLL | P1,2,3 |
| MG-(T43K) | + | + | NLL | NLL | P1,2 |
| MG-(D50G) | + | + | NLL | NLL | P1,2 |
| MG-(L13F+G66V)a | + | + | + | NLL | P1,2,3 |
| MG-(L13F) | + | + | NLL | NLL | P1,2 |
| MG-(G66V) | + | + | NLL | NLL | P1,2 |
| MG-(A86G) | + | + | + | + | P1,2,3,4 |
This mutation was also introduced in P1,2 clone TS, as reported by Moreno-Pérez et al. (25).
+, systemic infection; NLL, resistance expressed as necrotic local lesions.